Division of Cardiology, Department of Medicine, Northwestern University, Chicago, Illinois.
Division of Cardiovascular Medicine, Department of Medicine, Stanford University, Stanford, California.
ASAIO J. 2022 May 1;68(5):646-653. doi: 10.1097/MAT.0000000000001558. Epub 2021 Aug 16.
Acute renal failure (ARF) and chronic kidney disease (CKD) are associated with short- and long-term morbidity and mortality following heart transplantation (HT). We investigated the incidence and risk factors for developing ARF requiring hemodialysis (HD) and CKD following HT specifically in patients with a left ventricular assist device (LVAD). We examined the International Society for Heart and Lung Transplantation (ISHLT) Thoracic Transplant Registry for heart transplant patients between January 2000 and June 2015. We compared patients bridged with durable continuous-flow LVAD to those without LVAD support. Primary outcomes were ARF requiring HD before discharge following HT and CKD (defined as creatinine >2.5 mg/dl, permanent dialysis, or renal transplant) within 3 years. There were 18,738 patients, with 4,535 (24%) bridged with LVAD support. Left ventricular assist device patients had higher incidence of ARF requiring HD and CKD at 1 year, but no significant difference in CKD at 3 years compared to non-LVAD patients. Among LVAD patients, body mass index (BMI) (odds ratio [OR] = 1.79, p < 0.001), baseline estimated glomerular filtration rate (eGFR) (OR = 0.43, p < 0.001), and ischemic time (OR = 1.28, p = 0.014) were significantly associated with ARF requiring HD. Similarly, BMI (hazard ratio [HR] = 1.49, p < 0.001), baseline eGFR (HR = 0.41, p < 0.001), pre-HT diabetes mellitus (DM) (HR = 1.37, p = 0.011), and post-HT dialysis before discharge (HR = 3.93, p < 0.001) were significantly associated with CKD. Left ventricular assist device patients have a higher incidence of ARF requiring HD and CKD at 1 year after HT compared with non-LVAD patients, but incidence of CKD is similar by 3 years. Baseline renal function, BMI, ischemic time, and DM can help identify LVAD patients at risk of ARF requiring HD or CKD following HT.
急性肾衰竭 (ARF) 和慢性肾脏病 (CKD) 与心脏移植 (HT) 后短期和长期发病率和死亡率相关。我们专门研究了在接受左心室辅助装置 (LVAD) 的患者中,HT 后需要血液透析 (HD) 的 ARF 和 CKD 的发生率和危险因素。我们检查了国际心肺移植协会 (ISHLT) 胸科移植登记处 2000 年 1 月至 2015 年 6 月之间的心脏移植患者。我们将接受耐用性连续流动 LVAD 桥接的患者与未接受 LVAD 支持的患者进行了比较。主要结局是 HT 后出院前需要 HD 的 ARF 和 3 年内的 CKD(定义为肌酐 >2.5mg/dl、永久性透析或肾移植)。共有 18738 名患者,其中 4535 名(24%)接受了 LVAD 支持。LVAD 患者在 1 年内 ARF 需要 HD 和 CKD 的发生率较高,但与非 LVAD 患者相比,3 年内 CKD 无显著差异。在 LVAD 患者中,体重指数 (BMI)(比值比 [OR] = 1.79,p < 0.001)、基线估计肾小球滤过率 (eGFR)(OR = 0.43,p < 0.001)和缺血时间(OR = 1.28,p = 0.014)与需要 HD 的 ARF 显著相关。同样,BMI(风险比 [HR] = 1.49,p < 0.001)、基线 eGFR(HR = 0.41,p < 0.001)、HT 前糖尿病 (DM)(HR = 1.37,p = 0.011)和 HT 后出院前透析(HR = 3.93,p < 0.001)与 CKD 显著相关。与非 LVAD 患者相比,LVAD 患者在 HT 后 1 年内 ARF 需要 HD 和 CKD 的发生率较高,但 3 年后 CKD 的发生率相似。基线肾功能、BMI、缺血时间和 DM 有助于识别 LVAD 患者在 HT 后发生 ARF 需要 HD 或 CKD 的风险。